Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"

被引：1
|
作者：
Sullivan, Ivana [1 ]
Planchard, David [1 ]
机构：
[1] Gustave Roussy, Dept Med Oncol, 114 Rue Edouard Vaillant, F-94800 Villejuif, France
来源：
JOURNAL OF THORACIC DISEASE | 2016年 / 8卷 / 10期
关键词：
ADULT PATIENTS PTS; ALK-INHIBITOR; CONFER RESISTANCE; SINGLE-ARM; OPEN-LABEL; CRIZOTINIB; NSCLC; CERITINIB; CHEMOTHERAPY; MUTATIONS;
D O I：
10.21037/jtd.2016.10.57
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1287 / E1292
页数：6
相关论文
共 50 条
  • [21] Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
    Wakelee, H.
    Reckamp, K. L.
    Leal, T. A.
    Patel, S. P.
    Blumenschein, G.
    Shum, E.
    Nieva, J.
    Oxnard, G.
    Sanborn, R. E.
    Waqar, S.
    Zeman, K.
    Dukart, G.
    Harrow, K.
    Liang, C.
    Holzhausen, A.
    Horn, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [22] Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
    Singh, Abhay
    Chen, Hongbin
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6615 - 6628
  • [23] Brigatinib as a treatment of ALK-positive non-small cell lung cancer
    De Carlo, Elisa
    Stanzione, Brigida
    Del Conte, Alessandro
    Revelant, Alberto
    Bearz, Alessandra
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (05): : 299 - 305
  • [24] Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
    Rijavec, Erika
    Biello, Federica
    Indini, Alice
    Grossi, Francesco
    Genova, Carlo
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 1 - 9
  • [25] Economic evaluation of crizotinib, alectinib, ceritinib, and brigatinib in treatment naive anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Halawah, Hala
    Calamia, Matthias
    Gulick, Dexter
    Manasrah, AlMothana
    Alkhdour, Odai
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] BRIGATINIB AS A LEADING OPTION TO MANAGE PREVIOUSLY NOT TREATED PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (ALK plus NSCLC) IN PORTUGAL
    Monteiro, S.
    Labisa, P.
    Fragoso, J.
    Ferreira, C.
    Cochado, S.
    VALUE IN HEALTH, 2022, 25 (01) : S90 - S90
  • [27] Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase-positive non-small cell lung cancer
    Gupta, Neeraj
    Hanley, Michael J.
    Sinha, Vikram
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (08) : 3922 - 3923
  • [28] Real-World Brigatinib Dosing Patterns in Patients with Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer in the United States
    Lin, H.
    Wu, Y.
    Gorritz, M.
    Mcguiness, C.
    Huang, W.
    Chen, C.
    Ren, K.
    Camidge, R.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S661 - S661
  • [29] Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive, advanced non -small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
    Kim, Edward S.
    Ou, Sai-Hong Ignatius
    Barlesi, Fabrice
    Mok, Tony S. K.
    Ahn, Myung-Ju
    Bunn, Veronica
    Zhang, Pingkuan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
    Passaro, A.
    Prelaj, A.
    Pochesci, A.
    Spitaleri, G.
    Rossi, G.
    Del Signore, E.
    Catania, C.
    de Marinis, F.
    DRUGS OF TODAY, 2017, 53 (08) : 435 - 446
12345